Effect of low glucose degradation product peritoneal dialysis solution Gambrosol-Trio on residual renal function in patients receiving peritoneal dialysis - a randomized controlled trial
Not Applicable
Completed
- Conditions
- End stage renal failureNutritional, Metabolic, Endocrine
- Registration Number
- ISRCTN26252543
- Lead Sponsor
- Institute of Kidney Lifescience Technologies (Canada)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 98
Inclusion Criteria
1. Age 18 years or above
2. Able to give consent
3. Patient with Peritoneal Dialysis (PD) catheter inserted
Exclusion Criteria
1. Age less than 18
2. Previous hemodialysis
3. Those unlikely to continue peritoneal dialysis for more than six months due to severe comorbid conditions, planned living renal transplantation, or planned transfer to another facility
4. Patients with previous renal transplant
5. Patients starting incremental peritoneal dialysis
6. 24-hour urine volume of less than 100 ml and/or creatinine clearance of less than 1 ml/min
7. Patients with psychiatric diagnoses that might impinge on compliance
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Rate of decline of residual renal function
- Secondary Outcome Measures
Name Time Method 1. Peritoneal ultrafiltration<br>2. Peritonitis episodes<br>3. Cardiovascular events (combination of non-fatal myocardial infarction [MI], peripheral vascular disease requiring lower limb amputation, strokes, and deaths due to cardiovascular causes) <br>4. Peritoneal equilibration test results<br>5. Peritoneal clearances of urea and creatinine<br>6. Changes in dialysate CA125 and advanced glycosylated end products